Vemurafenib plus rituximab is not recommended to be available as a routinely commissioned treatment option for adult patients with classic hairy cell leukaemia (HCL) who are either a) refractory to first-line treatment with a purine analogue (PA) therapy; or b) refractory to, or relapse following, treatment with a second-line purine analogue (PA) therapy with or without rituximab; or c) for patients who are unsuitable for PA therapy at any time.

The policy is restricted to certain age groups as there is insufficient evidence to confirm safety and/or it is not recommended through the licence authorisation process to be used in those age groups not included in the policy.